Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 380 resultater
Tid
Selskap
Tittel
Sektor
Kategori
18 Nov 2024
07:00 CET
IPSEN
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
20103015 Pharmaceuticals
-
18 Nov 2024
07:00 CET
IPSEN
Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG
20103015 Pharmaceuticals
-
15 Nov 2024
17:00 CET
IPSEN
Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit
20103015 Pharmaceuticals
-
15 Nov 2024
17:00 CET
IPSEN
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
20103015 Pharmaceuticals
-
07 Nov 2024
18:00 CET
IPSEN
Ipsen - Octobre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
07 Nov 2024
18:00 CET
IPSEN
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
23 Oct 2024
07:00 CEST
IPSEN
Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2024 et revoit à la hausse ses prévisions pour l'exercice en cours
20103015 Pharmaceuticals
Commercial results
23 Oct 2024
07:00 CEST
IPSEN
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
20103015 Pharmaceuticals
Commercial results
14 Oct 2024
18:00 CEST
IPSEN
Ipsen receives its second Shingo Prize for operational excellence
20103015 Pharmaceuticals
-
14 Oct 2024
18:00 CEST
IPSEN
Ipsen reçoit un deuxième prix Shingo pour son excellence opérationnelle
20103015 Pharmaceuticals
-
09 Oct 2024
18:00 CEST
IPSEN
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
09 Oct 2024
18:00 CEST
IPSEN
Ipsen - Septembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
23 Sep 2024
13:13 CEST
IPSEN
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
20103015 Pharmaceuticals
-
23 Sep 2024
13:13 CEST
IPSEN
Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union européenne pour le prurit cholestatique lié au syndrome d’Alagille, une maladie hépatique rare
20103015 Pharmaceuticals
-
20 Sep 2024
14:57 CEST
IPSEN
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
20103015 Pharmaceuticals
-
20 Sep 2024
14:57 CEST
IPSEN
Le médicament Iqirvo® (élafibranor) d’Ipsen est approuvé dans l’Union européenne comme premier nouveau traitement contre la cholangite biliaire primitive depuis près d’une décennie
20103015 Pharmaceuticals
-
16 Sep 2024
14:45 CEST
IPSEN
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
20103015 Pharmaceuticals
Other subject
16 Sep 2024
14:45 CEST
IPSEN
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
20103015 Pharmaceuticals
Other subject
15 Sep 2024
14:45 CEST
IPSEN
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
20103015 Pharmaceuticals
Other subject
15 Sep 2024
14:45 CEST
IPSEN
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
20103015 Pharmaceuticals
Other subject
04 Sep 2024
18:00 CEST
IPSEN
Ipsen - Août 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
04 Sep 2024
18:00 CEST
IPSEN
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
13 Aug 2024
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 32 - 2024
20103015 Pharmaceuticals
Share history
13 Aug 2024
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024
20103015 Pharmaceuticals
Share history
06 Aug 2024
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024
20103015 Pharmaceuticals
Share history
06 Aug 2024
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2024
20103015 Pharmaceuticals
Share history
05 Aug 2024
18:00 CEST
IPSEN
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
05 Aug 2024
18:00 CEST
IPSEN
Ipsen - Juillet 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
30 Jul 2024
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
20103015 Pharmaceuticals
Share history
30 Jul 2024
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2024
20103015 Pharmaceuticals
Share history
26 Jul 2024
12:46 CEST
IPSEN
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
20103015 Pharmaceuticals
-
26 Jul 2024
12:46 CEST
IPSEN
Ipsen reçoit des avis positifs du CHMP pour Iqirvo® (elafibranor) dans la cholangite biliaire primitive et Kayfanda® (odévixibat) dans le syndrome d'Alagille, deux maladies rares du foie cholestatiques
20103015 Pharmaceuticals
-
25 Jul 2024
14:18 CEST
IPSEN
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
20103015 Pharmaceuticals
Other subject
25 Jul 2024
14:18 CEST
IPSEN
Ipsen S.A.publie son Rapport financier semestriel 2024 (semestre clos le 30 juin 2024)
20103015 Pharmaceuticals
Other subject
25 Jul 2024
07:00 CEST
IPSEN
Ipsen publie de solides résultats pour le premier semestre 2024, progresse sur ses lancements et revoit à la hausse ses objectifs pour l’exercice en cours
20103015 Pharmaceuticals
Commercial results
25 Jul 2024
07:00 CEST
IPSEN
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
20103015 Pharmaceuticals
Commercial results
25 Jul 2024
06:58 CEST
IPSEN
Ipsen et Day One concluent un accord exclusif de licence hors États-Unis pour commercialiser le tovorafénib contre la forme la plus courante de tumeur cérébrale chez l’enfant
20103015 Pharmaceuticals
-
25 Jul 2024
06:58 CEST
IPSEN
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
20103015 Pharmaceuticals
-
23 Jul 2024
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 29 - 2024
20103015 Pharmaceuticals
Share history
23 Jul 2024
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
20103015 Pharmaceuticals
Share history
16 Jul 2024
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
20103015 Pharmaceuticals
Share history
16 Jul 2024
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 28 - 2024
20103015 Pharmaceuticals
Share history
11 Jul 2024
07:00 CEST
IPSEN
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
20103015 Pharmaceuticals
-
11 Jul 2024
07:00 CEST
IPSEN
Ipsen et Foreseen Biotechnology annoncent la signature d’un accord exclusif de licence mondiale pour un conjugué anticorps-médicament doté d'un potentiel de première classe
20103015 Pharmaceuticals
-
09 Jul 2024
18:00 CEST
IPSEN
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
09 Jul 2024
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
20103015 Pharmaceuticals
Share history
09 Jul 2024
18:00 CEST
IPSEN
Ipsen - Juin 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
09 Jul 2024
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2024
20103015 Pharmaceuticals
Share history
08 Jul 2024
18:00 CEST
IPSEN
Half-year statement of IPSEN liquidity agreement - 2024 06 30
20103015 Pharmaceuticals
Share history
08 Jul 2024
18:00 CEST
IPSEN
Bilan semestriel du contrat de liquidité d'IPSEN - 2024 06 30
20103015 Pharmaceuticals
Share history
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva